We are live on ! Find out more
NVCR icon

NovoCure

238 hedge funds and large institutions have $1.24B invested in NovoCure in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 100 increasing their positions, 61 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $5.74M

64% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 61

10% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 40

3.34% more ownership

Funds ownership: 82.04%85.38% (+3.3%)

4% more capital invested

Capital invested by funds: $1.19B → $1.24B (+$50.9M)

2% less funds holding

Funds holding: 244238 (-6)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
238
Holders Change
-6
Holders Change %
-2.46%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
44
Increased
100
Reduced
61
Closed
40
Calls
$16.7M
Puts
$5.74M
Net Calls
+$11M
Net Calls Change
-$5M
Name Holding Trade Value Shares
Change
Change in
Stake
PS
276
Principal Securities
Iowa
-$646 -50 Closed
QCG
277
Quadrant Capital Group
Ohio
-$530 -41 Closed

NVCR Hedge Fund Activity: Q4 2025 in Review

238 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2025, worth a combined $1.24B — up 4.3% from $1.19B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new NVCR positions and 40 closed out — a net gain of 4 holders — while 100 added to existing stakes and 61 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $53.3M. The largest seller was Capital World Investors, exiting entirely with an estimated $25.8M sold.

  • 238 institutional investors held NovoCure (NVCR) as of Q4 2025, down from 244 in Q3 2025.
  • Funds reported $1.24B of NovoCure stock for Q4 2025, up 4.3% quarter-over-quarter.
  • 44 funds opened new NovoCure positions in Q4 2025 and 40 closed out, a net change of +4 holders.
  • The largest NovoCure buyer in Q4 2025 was Morgan Stanley, an estimated $53.3M added.
  • The largest NovoCure seller in Q4 2025 was Capital World Investors, an estimated $25.8M sold.

Based on aggregated 13F filings for Q4 2025.